Evidence Grade E — Very limited evidence. 0 published studies. 0 registered clinical trials.
Medically reviewed by a licensed medical professional
PEG-MGF is a PEGylated version of MGF (Mechano Growth Factor), where a polymer chain is attached to extend its duration. No peer-reviewed studies of PEG-MGF as a defined product exist. The PEG chain length, attachment site, and resulting properties are not standardised — meaning products sold under this name may differ from one another. It is one of the least-characterised compounds in this database.
PEG-MGF is also known by these brand and alternate names:
No published studies found on PubMed.
PEG-MGF has no marketing authorisation. No peer-reviewed studies of PEG-MGF as a defined PEGylated peptide entity exist. The PEG chain length, attachment site, and resulting pharmacological properties are not standardised.
The absence of any characterisation studies means that products sold as PEG-MGF through unregulated channels have no defined molecular identity, no quality standards, and no basis for predicting their behaviour. This compound represents one of the least-characterised entries in this database.
Research suggests the same proposed mechanism as native MGF, with PEGylation extending the duration of action. However, no peer-reviewed studies of PEG-MGF as a specific, defined PEGylated peptide product have been published. Studies sometimes cited as PEG-MGF evidence actually used PEG-based hydrogel delivery systems for native MGF, which is a fundamentally different approach.
No peer-reviewed pharmacokinetic or pharmacodynamic data have been published for PEG-MGF. Studies sometimes cited as PEG-MGF evidence actually used different PEG-based delivery systems, not the same molecule. Additional PEGylation-specific concerns include anti-PEG antibody formation with repeated exposure (a documented phenomenon that can cause serious allergic reactions), altered tissue distribution, and potential PEG tissue accumulation. Products are essentially uncharacterised research chemicals. Products from unregulated channels lack pharmaceutical quality assurance.
PeptideTrace tracks 0 registered clinical trials for PEG-MGF sourced from ClinicalTrials.gov.
No trials registered on ClinicalTrials.gov for this compound.
PEG-MGF is the MGF 24-amino acid E-domain peptide (sequence: YQPPSTNKNTKSQRRKGSTFEEHK) with a polyethylene glycol (PEG) polymer chain covalently attached. The base peptide is approximately 2,972 Da; total molecular weight varies depending on PEG chain length, which is not standardized across manufacturers. PEGylation protects the peptide from rapid enzymatic degradation and reduces renal clearance, extending the half-life from MGF's approximately 5-7 minutes to an estimated several hours to possibly days, though these figures derive primarily from non-peer-reviewed sources and should be treated with significant caution. Research administration routes include subcutaneous and intramuscular injection.
Research suggests PEG-MGF operates through the same mechanism as native MGF: satellite cell activation and proliferation, PI3K/Akt pathway activation, and anti-apoptotic effects. The key distinction is that PEGylation converts MGF from an acute, local-pulse factor into a more sustained systemic agent, which may or may not preserve normal physiological signaling patterns. The PEG moiety is pharmacologically inert but alters biodistribution, extending circulation time through reduced renal filtration and protection from proteolytic degradation.
No peer-reviewed studies specifically characterizing 'PEG-MGF' as a defined PEGylated peptide entity exist on PubMed. Studies sometimes cited as PEG-MGF research actually used PEG-based hydrogel delivery platforms for native MGF peptide, which is fundamentally different from PEGylating the peptide itself. For example, Pena et al. (2015) delivered native MGF via PEGDMA microrods intramyocardially after coronary artery ligation in mice, achieving 100% survival at 2 and 10 weeks post-MI. All other evidence is extrapolated from the MGF literature. No clinical trials exist. No branded pharmaceutical product has been developed. The compound is not approved by any regulatory agency.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Compare prices from 7 vendor listings
View pricing data across vendors and countries for PEG-MGF
Somatrogon is marketed as Ngenla (approved June 2023) for paediatric growth hormone deficiency in children aged 3 years and older. In the pivotal trial, once-weekly somatrogon produced growth rates equivalent to daily somatropin injections (10.1 cm/year versus 9.8 cm/year), confirming that reducing injection frequency does not compromise growth outcomes. Ngenla represents a meaningful advance for paediatric patients and their families, reducing injections from 365 to 52 per year. Treatment adherence has been a persistent challenge with daily growth hormone, and weekly dosing is expected to improve long-term outcomes through better compliance. Somatrogon competes directly with somapacitan (Sogroya), the other approved weekly growth hormone, creating a new generation of less burdensome treatment options.
MGF has no marketing authorisation. No human clinical trials have been conducted. The evidence base consists of animal studies and cell culture experiments. A single mouse study reported increased muscle fibre size after intramuscular injection. The compound's very short half-life (estimated minutes) in its native form has led to the development of PEGylated versions (PEG-MGF, #105) in unregulated channels, though this creates a pharmacologically distinct molecule. Products available through unregulated channels lack pharmaceutical quality assurance.
Tesamorelin is marketed as Egrifta SV (approved November 2010) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. In clinical trials, it reduced visceral fat by approximately 15% compared to a 5% increase with placebo, and this reduction was sustained with continued treatment. Tesamorelin occupies a unique niche — it is the only approved GHRH analogue and the only medication specifically approved for HIV-associated lipodystrophy. Beyond its approved indication, it has attracted research interest for potential effects on liver fat, cognitive function, and peripheral neuropathy. Fat reduction reverses when treatment stops, and it is not approved for general weight loss or body composition purposes.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
